ProglumidePanc: Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor

Georgetown University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05827055

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase I open labelled study to treat patients with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with gemcitabine and nab-paclitaxel given days 1, 8, and 15 every 28 days, and proglumide. This is a phase 1 study with 3+3 design, enrolling 3-12 patients over 2 planned dose levels of proglumide (maximum 6 patients per dose level). Proglumide will be tested at the daily dose of 1200 mg orally (PO) given as 400 mg three times daily (TID) (dose level 1) or 1600 mg orally (PO) given as 800 mg twice a day (BID) (dose level 2). All cycles are 28 days. Patients will be monitored for safety and toxicity by laboratory blood testing and physical examinations.

Condition or Disease	Intervention/Treatment	Phase
Metastatic Pancreatic Cancer	Drug: Gemcitabine Drug: Nab paclitaxel Drug: Proglumide Dose level 1 Drug: Proglumide Dose level 2	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

12 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Study of Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Anticipated Study Start Date :

Jul 1, 2023

Anticipated Primary Completion Date :

Jul 1, 2026

Anticipated Study Completion Date :

Jul 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dose Level 1: Proglumide TID with Gemcitabine and Nab-Paclitaxel Proglumide given three times a day with gemcitabine and nab-paclitaxel	Drug: Gemcitabine 1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle) Other Names: Gemzar Drug: Nab paclitaxel 125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle) Drug: Proglumide Dose level 1 Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) (dose level 1)
Experimental: Dose Level 2: Proglumide BID with Gemcitabine and Nab-Paclitaxel Proglumide given two times a day with gemcitabine and nab-paclitaxel	Drug: Gemcitabine 1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle) Other Names: Gemzar Drug: Nab paclitaxel 125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle) Drug: Proglumide Dose level 2 Daily dose of 1600 mg orally given as 800 mg orally (PO) twice a day (BID) (dose level 2).

Arm

Intervention/Treatment

Experimental: Dose Level 1: Proglumide TID with Gemcitabine and Nab-Paclitaxel

Proglumide given three times a day with gemcitabine and nab-paclitaxel

Drug: Gemcitabine

1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)

Other Names:

Gemzar

Drug: Nab paclitaxel

125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)

Drug: Proglumide Dose level 1

Daily dose of 1200 mg orally given as 400 mg orally (PO), three times a day (TID) (dose level 1)

Experimental: Dose Level 2: Proglumide BID with Gemcitabine and Nab-Paclitaxel

Proglumide given two times a day with gemcitabine and nab-paclitaxel

Drug: Gemcitabine

1000mg/m2 IV given days 1, 8, and 15 every 28 days (1 cycle)

Other Names:

Gemzar

Drug: Nab paclitaxel

125 mg/m2 given days 1, 8, and 15 every 28 days (1 cycle)

Drug: Proglumide Dose level 2

Daily dose of 1600 mg orally given as 800 mg orally (PO) twice a day (BID) (dose level 2).

Outcome Measures

Primary Outcome Measures

Proglumide Recommended Phase II dose and schedule (RP2D) [2 years]
Determination of the recommended phase II dose and schedule (RP2D) of proglumide in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Secondary Outcome Measures

Overall survival (OS) [through 2 years after end of treatment]
median overall survival will be estimated using Kaplan-Meier curves.
Progression-free survival [2 years]
median progression free survival will be estimated using Kaplan-Meier curves.
Objective response rate by RECIST v. 1.1 [2 years]
Every 8 weeks (± 7 days) radiographic imaging (CT or MRI) will be done to assess tumor burden according to RECIST v. 1.1
Change in tumor marker (CA19-9) [2 years]
Maximum percent decrease in CA19-9 will be analyzed.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Written informed consent and any locally-required authorization (e.g., HIPAA in the USA) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
Age > 18 years at time of study entry.
Adequate normal organ and marrow function as defined below:

Hemoglobin ≥ 9.0 g/dL
Absolute neutrophil count (ANC) > 1500 per mm3
Platelet count ≥100,000 per mm3)
Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN).
AST and ALT ≤2.5 x ULN of normal unless liver metastases are present, in which case it must be ≤5x ULN
Creatinine clearance (CL) >60 mL/min using the Cockroft-Gault formula.

Evidence of post-menopausal status or negative urine or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments, or if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

Patients must have measurable disease by RECIST v1.1 and disease amenable to serial biopsy.
Subjects may not have received prior therapy with GEM/NAB-P.
Patients must have metastatic pancreatic ductal adenocarcinoma with adenocarcinoma as the dominant histology (biopsy-proven, primary tumor biopsy is acceptable for eligibility)
No prior systemic treatment for metastatic disease (neoadjuvant/adjuvant therapy is allowable but could not contain GEM or NAB-P).
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

Subjects with a concurrent malignancy or malignancy within 3 years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer, or localized prostate cancer following definitive therapy.
Subjects with uncontrolled cardiovascular diseases (congestive heart failure, symptoms of coronary artery disease, cardiac arrhythmias) or who have suffered a myocardial infarction in the preceding 6 months.
Blood anticoagulation that cannot be safely stopped for biopsy.
Subjects with poorly controlled medical conditions including asthma, chronic obstructive pulmonary disease, diabetes, seizure disorders, hepatic or renal failure.
Pregnant or nursing women.
Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence) prior to study entry, for the duration of study participation, and for 6 months thereafter.
Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
History of allogenic organ transplantation.
Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea or inability to digest and absorb pills, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).

Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.
Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Testing for tuberculosis, hepatitis B and C and HIV is not a requirement for screening for the clinical trial.

Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational drug. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last dose of IP.
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of proglumide therapy.
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Patient is unable to swallow pills or has a malabsorption syndrome that would not enable the patient to properly absorb proglumide.